ArticleSubstance use : research and treatment

Self-Reported Cognitive Impairments in Office-Based Treatment for Opioid Use Disorder with Buprenorphine or Extended-Release Naltrexone.

Efrat Aharonovich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.